The First Case of Therapy-Related Myelomastocytic Leukemia Based on the WHO 2008 Classification and the Recently Proposed Diagnostic Criteria

• Published in: Annals of laboratory medicine Vol. 37; no. 3; pp. 282 - 284
• Main Authors: Choi, Won Kyu, Cho, Young Uk, You, Eunkyoung, Jang, Seongsoo, Seo, Eul Ju, Park, Chan Jeoung
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society for Laboratory Medicine 01.05.2017; 대한진단검사의학회
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow - pathology; Carboplatin - administration & dosage; Female; Humans; Immunophenotyping; Karyotype; Letter to the Editor; Leukemia, Mast-Cell - classification; Leukemia, Mast-Cell - diagnosis; Leukemia, Mast-Cell - etiology; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Paclitaxel - administration & dosage; World Health Organization; 병리학
• ISSN: 2234-3806; 2234-3814
• DOI: 10.3343/alm.2017.37.3.282

Dear Editor, AML is occasionally associated with bone marrow (BM) mastocytosis. Differential diagnoses include reactive mast cell (MC) hyperplasia, systemic mastocytosis (SM) with associated clonal hematological non-MC lineage disease, and MC leukemia (MCL) [1]. Myelomastocytic leukemia (MML) is a new classification for AML patients who show an increase in immature and atypical MCs, but who do not fulfill the criteria for MCL or SM [2-7]. Here, we describe for the first time a case of therapy-related MML, and review key elements of differential diagnosis in patients with myeloid neoplasms and BM mastocytosis [8, 9]. KCI Citation Count: 0